Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-020854
Filing Date
2025-02-14
Accepted
2025-02-14 13:18:00
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 11318
2 EX-99.1 ck0001669811-ex99_1.pdf EX-99.1 121023
  Complete submission text file 0000950170-25-020854.txt   180161
Mailing Address 12 PENNS TRAIL NEWTOWN PA 18940
Business Address 12 PENNS TRAIL NEWTOWN PA 18940 267-759-3680
Traws Pharma, Inc. (Subject) CIK: 0001130598 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-87566 | Film No.: 25626122
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 100 CRESCENT COURT SUITE 1620 DALLAS TX 75201
Business Address 100 CRESCENT COURT SUITE 1620 DALLAS TX 75201 214-364-2883
Ikarian Capital, LLC (Filed by) CIK: 0001778253 (see all company filings)

EIN.: 473466768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G